Vilazodone submission set for 2009
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Newton, Mass.-based Clinical Data expects to file an NDA for its depression candidate vilazodone in 2009, the firm says Dec. 17. A long-term safety study initiated ahead of schedule in December, along with a second pivotal Phase III trial expected to begin in early 2008, will support the NDA for the dual serotonergic agent, which was licensed from Merck KGaA in September 2004. The second pivotal trial will evaluate a pharmacogenetic test developed in the recently completed first pivotal trial to assist physicians in predicting patients' response to vilazodone...
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.